EGIS-7625

EGIS-7625
Clinical data
ATC code	none;
Legal status
Legal status	UN: Unscheduled;
Identifiers
	IUPAC name 5-(4-Benzylpiperazin-1-yl)-2-methyl-4-nitroaniline;
CAS Number	755040-97-2;
PubChem CID	9930789;
ChemSpider	8106420;
UNII	VVM6OT854G;
CompTox Dashboard (EPA)	DTXSID701177281 ;
Chemical and physical data
Formula	C18H22N4O2
Molar mass	326.400 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC(=C(C=C1N)N2CCN(CC2)CC3=CC=CC=C3)[N+](=O)[O-];
	InChI InChI=1S/C18H22N4O2/c1-14-11-18(22(23)24)17(12-16(14)19)21-9-7-20(8-10-21)13-15-5-3-2-4-6-15/h2-6,11-12H,7-10,13,19H2,1H3; Key:ZEFXWOMFCPRXJW-UHFFFAOYSA-N;

EGIS-7625 is a selective and competitive 5-HT_2B receptor antagonist. It is experimentally proven to be directly associated with smooth stomach muscle constriction of white rats in vivo, and variably effective in provoking a similar response in in vitro human stomach cells. In high blood concentrations, it causes mild constriction of rabbit pulmonary arteries.^[1]

References

^ Kovács A, Gacsályi I, Wellmann J, Schmidt E, Szücs Z, Dubreuil V, et al. (2003). "Effects of EGIS-7625, a selective and competitive 5-HT2B receptor antagonist". Cardiovascular Drugs and Therapy. 17 (5–6): 427–34. doi:10.1023/B:CARD.0000015857.96371.43. PMID 15107597. S2CID 11532969.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[pmid15107597-1] Kovács A, Gacsályi I, Wellmann J, Schmidt E, Szücs Z, Dubreuil V, et al. (2003). "Effects of EGIS-7625, a selective and competitive 5-HT2B receptor antagonist". Cardiovascular Drugs and Therapy. 17 (5–6): 427–34. doi:10.1023/B:CARD.0000015857.96371.43. PMID 15107597. S2CID 11532969.

[1]